Opening hours – Spring 2019
"Cell-line of the month" - IL-23
Why do colony stimulating factors have unique biological roles offering therapeutic benefits?
Introducing iLite Granulocyte Colony-Stimulating Factor (G-CSF) Responsive Cell Line
Introducing iLite® Assay Ready Cells for IL-2 and IL-6
Why are interleukins interesting targets in biological drug compounds?
Cell line of the month - FGF21
Introducing Complement TCC - The newest addition to the Svar Life Science Complement range
New tests & updates to our 2019 Diagnostic Test Portfolio
Website Launch

News archive

"Cell-line of the month" - IL-23

iLite® IL-23 - offering significant benefits compared to conventional IL-23 assays

Targeting of IL-23 or the IL-23 receptor is a potential therapeutic approach for autoimmune diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis.

IL-23 is a pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions. Emerging data demonstrate that IL-23 is a key participant in central regulation of the cellular mechanisms involved in inflammation and therapeutic agents targeting both IL-23 and IL-12 cytokines are currently used to treat psoriasis and psoriatic arthritis. In addition, related agents are in clinical testing for a variety of inflammatory disorders.


The iLite® IL-23 Assay Ready Cells is derived from a highly specific reporter gene cell line that can discriminate on a subunit level between the sometime cross reactive IL-23 and IL-12 and subsequently be used for quantifying IL-23 activity, IL-23 inhibitor activity, e.g. Ustekinumab and the activity of neutralizing antibodies against the latter.

iLite® Cell-Based Assays
Valuable tools during the whole drug development continuum

iLite® cell lines can be developed for any biopharmaceutical target,  and assays for drug potency, i.e. drug activity, and neutralizing antibodies (NAbs) can easily be set-up using the same cell line. The iLite® technology eliminates many of the limitations of conventional cell-based assays as the cells are delivered as assay ready frozen cells, allowing cell-based assays to be carried out without the need for cell culture or the maintenance of cells continuously in the laboratory.

This allows for significant cost reductions and increases the applicability of cell-based assays to routine use as potency or neutralization assays.

For more information about our iLite® Assay Ready Cells - please click here.

Why do colony stimulating factors have unique biological roles offering therapeutic benefits?

Colony-stimulating factors (CSF:s) activate and cause the cells to proliferate and differentiate into a specific kind of blood cell, usually white blood cells. There are different types of CSF:s and they have unique biological roles, indicating therapeutic benefits for a number of disease treatments ranging from different cancer forms, viral infections, and autoimmune diseases and as a result, many clinical trials targeting colony-stimulating factors are now well on their way.

Colony-stimulating factors (CSF:s) are secreted glycoproteins that bind to receptor proteins on the surfaces of hematopoietic stem cells, thereby activating intracellular signaling pathways that can cause the cells to proliferate and differentiate into a specific kind of blood cell, usually white blood cells. They play a part in the hosts´ response to injury and infection, and although they were originally defined as hematopoietic cell growth factors, CSF:s have been shown to have additional unique biological functions, suggesting that they could be used to target specific conditions. 

There is a great interest in targeting CSF:s in inflammatory and autoimmune disorders, as well as in cancer. Most CSF compounds of today are pharmaceutical analogs of CSF:s, where Filgrastim, a recombinant form of G-CSF, is the most well known. These therapies can be expensive and require cumbersome administration. New CSF analogues are represented primarily by biosimilars where the originator drug has gone off patent.

Click to learn more about the CSF family, their mechanism of actions, role as pharmaceutical targets and how the novel iLite® growth factor targets enable the study and targeting of human growth factor proteins and their receptors. 

Read more

Introducing iLite Granulocyte Colony-Stimulating Factor (G-CSF) Responsive Cell Line

MALMÖ, Sweden– February 27, 2019

Following on from the successful launch of IL-2 and IL-6, two new interleukin cell lines, Svar Life Science now introduces another new cell line for use in the growth factor segment - iLite® Assay Ready Cells for G-CSF. 

Granulocyte Colony-Stimulating Factor (G-CSF) is a type of growth factor that impacts the treatment and survival of patients and is used after chemotherapy to help white blood cells recover after treatment or before and after a stem cell transplant.

Designed to be highly specific, with simple and quick protocols, the iLite G-CSF Assay Ready Cells offer a large signal to noise ratio, high matrix tolerance and have high reproducibility.

The world market for G-CSFs is growing rapidly and a major force is the development of G-CSF biosimilars - due to the expiry of existing patents there is considerable interest from many companies to enter the marketplace. A number of biosimilar compounds of traditional G-CSF drugs are in clinical development and the iLite® Platform offers cell-based assays that enable the study and targeting of human growth factor proteins and their receptors. With the advantage of a biologically relevant assay system offering functional and quantitative read-outs, the iLite cell-based assay enables broad usage in applications such as functional screening, functional characterization, QC lot release (potency) assays and neutralizing antibody studies.

The assays are designed as Assay Ready Cells, giving you instant access to your assay. These cell-based assays can also be set up by our in-house GLP and GCP compliant laboratory Wieslab, offering bioanalytical services within (PK/PD), immunogenicity (ADA/NAb) and potency.

“We are delighted to announce several new cell lines during 2019 within our key focus areas. These additions to our cell-based portfolio will support extensions of use for already established products and reflect our continuing investment in the iLite cell-based solution platform” says Therese Segerstein, Product Manager Cell-based Solutions.

Learn more about "Colony Stimulating Factors - their unique biological roles and therapeutic benefits" in our blog post.

View Product Launch Update 

Introducing iLite® Assay Ready Cells for IL-2 and IL-6

MALMÖ, Sweden,– February 18, 2019

Svar Life Science, today announced the launch new interleukin cell lines adding to the iLite® portfolio of call-based solutions. These two new products are designed to be highly specific, with simple and quick protocols, large signal to noise ratio, high matrix tolerance and have high reproducibility.

”We are strengthening the cell-based interleukin portfolio with the addition of the iLite® IL-2 and IL- 6. These cell lines broaden our offering within interleukin related disease areas, and they nicely complement our other assay solutions already appreciated by pharmaceutical clients” says Therese Segerstein, Product Manager Cell-based Solutions.

Interleukins have shown to have a pivotal role in the mediation of physiological response to infection and as they contribute significantly to the functional changes that accompany a particular disease or disorder, it has become evident that they represent a group of proteins with potential importance as therapeutic targets.

The iLite® Platform offers cell-based assays that enable the study and targeting of human interleukin proteins and their receptors, while addressing these issues. The assays are designed as Assay Ready Cells and the cell-based assays can also be set up by our in-house laboratory Wieslab offering bioanalytical services in compliance with GLP and GCP.

This enables their broad usage in applications such as functional screening, functional characterization, QC lot release (potency) assays and neutralizing antibody studies. 

“We are always ready to assist clients in accelerating their drug discovery and development programs in the most efficient way by supporting with unique reporter gene assays and tailored laboratory service solutions” adds Therese Segerstein.

 

Learn more about "Why are interleukins interesting targets in biological drug compounds" in our blog post.

View Product Launch Update 

Why are interleukins interesting targets in biological drug compounds?

Interleukins have a pivotal role in the mediation of the physiological response to infection, immune response and contribute significantly to the functional changes that accompany a particular disease or a wide range of disorders. They are a group of naturally occurring proteins that mediate communication between cells and therefore have great potential as therapeutic targets. 

Several interleukins have already become successful treatment targets and many more are in early development or in different stages of clinical trials. These therapies are an increasingly important class of drugs in the treatment and management of many diseases and the main message is that interleukin therapeutics is a rapidly growing field with major pharmaceutical impact.

Click to learn more about the function and signaling of interleukins, potential therapeutic applications and the novel iLite® interleukin targets. 

Read more

 

Cell line of the month - FGF21

iLite® FGF21 Responsive Reporter Gene Cell Line With Improved Sensitivity

FGF21 holds promise to become a powerful drug in the treatment of a wide array of chronic human diseases, demonstrating that novel and potentially better medicines are within reach.

Fibroblast growth factor 21 (FGF21) is a hot target within the diabetes and obesity research and drug discovery. Known to function as an endocrine hormone with documented beneficial metabolic effects, FGF21 has been established as a viable, and excellent drug candidate molecule for therapeutic treatment of diabetes and cardiovascular disease associated with obesity.

The iLite® FGF21 Assay Ready Cells are genetically engineered reporter gene cells responsive to FGF21 by specific and proportional expression of Firefly Luciferase. As transmembrane protein β-Klotho has been identified as the necessary co-receptor able to permit FGF21 mediated activation of FGFRs in vitro and promote FGF21 action in vivo, the receptor chain FGFR1c in this new and improved cell line is overexpressed on the surface together with the co-factor β-Klotho which has been genetically optimized to enhance sensitivity.

FGF21 holds promise to eventually become a powerful drug in the treatment of a wide array of chronic human diseases, demonstrating that novel and potentially better medicines are within the reach.

iLite® Cell-Based Assays
Valuable tools during the whole drug development continuum

iLite® cell lines can be developed for any biopharmaceutical target,  and assays for drug potency, i.e. drug activity, and neutralizing antibodies (NAbs) can easily be set-up using the same cell line. The iLite® technology eliminates many of the limitations of conventional cell-based assays as the cells are delivered as assay ready frozen cells, allowing cell-based assays to be carried out without the need for cell culture or the maintenance of cells continuously in the laboratory.

This allows for significant cost reductions and increases the applicability of cell-based assays to routine use as potency or neutralization assays.

For more information about our iLite® Assay Ready Cells - please click here.

Website Launch

We’ve launched our new website and we’re excited to introduce you to our new look!

Svar Life Science is proud to announce the launch of our new website which coincides with us transitioning into a new brand and expanding our role as your partner for researching diagnostic strategies for personalized medicine and developing companion diagnostics based on assays customized for you. 

Our new website provides a clear message of who we are, what we stand for and and how we invent, develop and apply the best analytical technologies for drug development and clinical research, and establish practical platforms for routine diagnosis.

The website also boasts a clean Scandinavian design and consistent site-wide search system with improved menu functionality. It is also fully responsive with mobile devices, making it easy to navigate on a wide range of web browsers and portable devices.

We will continue to introduce a range of new content to the website and build a knowledge repository for to help you make the right decisions about partnering up with us, our laboratory services or purchasing our products. We also plan to continue adding more content about how we can help to push the boundaries in drug discovery and clinical diagnostics and provide you with all of the information you need to evaluate our products and services.

We’re really proud of the new website and feel it will create the experience you’re looking for when you pay us a visit. Svar means answers in Swedish. If you have questions, we can help you find the right answers. Contact us today.